
News|Articles|August 25, 2025
ESC Congress 2025: 7 Trials to Watch
Author(s)Ryan Livingston
Fact checked by: Victoria Johnson
Take a look at 7 major clinical trials to keep an eye on for the upcoming ESC Congress from August 29-September 1, 2025.
Advertisement
Advertisement
The European Society of Cardiology (ESC) will kick off its 2025 annual meeting in Madrid, Spain, on August 29, 2025. Championing the diverse knowledge, innovation, and expertise of the global
Related to this article

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.

The FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.

Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.

Children with eosinophilic esophagitis treated with dupilumab before age 6 had about half the asthma incidence of matched untreated peers 3.5 years later.
Advertisement
Advertisement

